Peter Wung Senior Vice President, Clinical Development | Peter has nearly 15 years of industry and clinical development experience in early and late phases covering small and large molecules along with cellular therapy across multiple therapeutic areas including rheumatology, allergy, dermatology, pulmonology, gastroenterology, and neurology. At AbbVie, Peter was the Global Development Lead for the JAK inhibitor program, upadacitinib. Previously, at Sanofi, he led a global clinical development team in the successful execution of the late phase immunology portfolio that included dupilumab (IL-4/13 inhibitor), sarilumab (IL-6 inhibitor), romilkimab (IL-4/13), and other compounds.  He has also served as the global medical lead on several successful large clinical programs including ixekizumab (IL-17 inhibitor) and tildrakizumab (IL-23 inhibitor) during his employment with a large CRO. Most recently, he was at Kyverna as the Vice President of Clinical Development and Operations in the development of CD19 CAR-T program.   

Prior to joining industry, Peter was at Johns Hopkins where he was an internal medicine resident and a rheumatology fellow with sub-specialized training in scleroderma and vasculitis before spending several years in a rheumatology private practice.  Peter obtained an M.D. from The Ohio State University, M.H.S. in Clinical Investigations from the Johns Hopkins University Bloomberg School of Public Health and B.S. in Computer Science from Case Western Reserve University.  He held previous academic appointments at Johns Hopkins Hospital and University of Texas Health Science Center at Houston and is board certified in rheumatology.